Vancomycin Dosing for Adults with Normal Renal Function
For average adults without renal impairment, administer vancomycin 15-20 mg/kg (based on actual body weight) every 8-12 hours, targeting trough concentrations of 15-20 mg/L for serious infections such as bacteremia, endocarditis, osteomyelitis, meningitis, and hospital-acquired pneumonia caused by S. aureus. 1
Standard Dosing Regimen
The FDA-approved usual daily intravenous dose is 2 g divided as either:
- 500 mg every 6 hours, or
- 1 g every 12 hours 2
However, these traditional fixed doses are inadequate for achieving optimal therapeutic targets in most patients. 1
Weight-Based Dosing (Preferred Approach)
Use 15-20 mg/kg per dose every 8-12 hours based on actual body weight to achieve target trough concentrations of 15-20 mg/L when the MIC is ≤1 mg/L. 1
Key Dosing Considerations:
For serious infections (bacteremia, endocarditis, osteomyelitis, meningitis, hospital-acquired pneumonia): Target trough concentrations of 15-20 mg/L to achieve an AUC/MIC ratio of ≥400. 1
When individual doses exceed 1 g (e.g., 1.5 g or 2 g): Extend the infusion period to 1.5-2 hours to minimize infusion-related reactions. 1
Standard infusion rate: No more than 10 mg/min or over at least 60 minutes, whichever is longer. 2
Concentration limits: Use concentrations no more than 5 mg/mL (up to 10 mg/mL in fluid-restricted patients, though this increases infusion-related event risk). 2
Loading Dose Strategy
Consider a loading dose of 25-30 mg/kg for seriously ill patients to achieve therapeutic concentrations more rapidly. 3, 4
A 25 mg/kg loading dose significantly increases the proportion of patients achieving target AUC₀₋₂₄ ≥400 mg·h/L (from 53.8% to 88.0%) without significantly increasing acute kidney injury risk. 3
Loading doses are associated with improved early clinical response (48-72 hours) in MRSA infections, even when steady-state trough concentrations are not immediately optimal. 4
Critical Limitations and Pitfalls
If the vancomycin MIC is 2 mg/L, conventional dosing cannot achieve the target AUC/MIC of ≥400 in patients with normal renal function (creatinine clearance 70-100 mL/min). In this scenario, consider alternative therapies. 1
Currently available nomograms were not developed to achieve these higher therapeutic targets, so individual pharmacokinetic adjustments are essential. 1
Monitoring Requirements
Measure steady-state trough concentration before the fourth dose for patients receiving prolonged courses. 1
Target trough: 15-20 mg/L for serious infections. 1
Do not monitor peak concentrations for nephrotoxicity reduction—this practice lacks supporting evidence. 1
Frequent monitoring is not necessary for short-course therapy (≤5 days) or lower-intensity dosing targeting troughs <15 mg/L. 1
Obesity Considerations
In obese patients without renal impairment, use 35 mg/kg/day (maximum 5500 mg/day) based on total body weight. 5
Vancomycin clearance and peripheral volume of distribution both increase with total body weight. 5
When given as twice-daily dosing, this regimen achieves >90% target attainment (AUC >400 mg·h/L) in individuals up to 200 kg, with corresponding trough concentrations of 5.7-14.6 mg/L. 5
Nephrotoxicity Monitoring
Define vancomycin-induced nephrotoxicity as ≥2-3 consecutive elevated serum creatinine measurements (increase of 0.5 mg/dL or 150% from baseline, whichever is greater) after several days of therapy, in the absence of alternative explanations. 1
Monitor trough concentrations closely in patients:
- Receiving aggressive dosing targeting sustained troughs of 15-20 mg/L 1
- At risk for toxicity (concurrent nephrotoxins) 1
- With unstable renal function 1
Higher vancomycin exposure (AUC₀₋₂₄ >400 mg·h/L) is associated with increased acute kidney injury risk (39.0% vs 14.8% for lower exposures). 3